AstraZeneca backs outlook as first quarter sales and profit beat hopes

(Alliance News) - AstraZeneca PLC on Wednesday reported better-than-expected first-quarter ...

Alliance News 29 April, 2026 | 8:17AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Wednesday reported better-than-expected first-quarter revenue and profit, and flagged the potential for its drugs pipeline amid numerous positive trial findings and regulatory approvals.

The Cambridge-based pharmaceuticals company said pretax profit increased 15% to USD3.91 billion in the three months to March 31 from USD3.40 billion the year prior, while diluted earnings per share improved 5.3% to USD1.97 from USD1.87.

Core operating profit rose 11% to USD5.35 billion from USD4.80 billion, or by 12% at constant exchange rates, ahead of Visible Alpha consensus of USD5.20 billion. Core EPS rose 3.6% to USD2.58 from USD2.49 on-year, or by 5% at CER, in line with consensus.

Revenue rose 13% to USD15.29 billion from USD13.59 billion a year ago, or by 8% at CER, ahead of VA consensus USD14.81 billion.

Cost of sales rose 20% to USD2.68 billion from USD2.24 billion, with research & developments expenses up 11% at USD3.49 billion from USD3.16 billion.

The FTSE 100 listing said growth was supported by double-digit gains in Oncology and Rare Disease, and progress in its late-stage pipeline with multiple positive trial readouts and regulatory approvals.

AstraZeneca highlighted 14 approvals alone in major regions since fourth quarter results.

Chief Executive Pascal Soriot said AstraZeneca delivered "strong growth" and is "advancing through our catalyst‑rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results."

AstraZeneca plans a total dividend of USD3.30 per share for 2026, up from USD3.20 a year before, and said it remains on track to meet its 2030 targets.

The group continues to expect revenue to grow by a mid-to-high single-digit percentage in 2026, with core earnings per share seen rising by a low double-digit percentage.

In 2025, the firm reported revenue of USD58.74 billion and core EPS of USD9.16.

By division, Oncology product revenue rose 16%, Cardiovascular, Renal & Metabolism sales fell 7%, Respiratory & Immunology grew 7%, Infectious Disease fell 22%, and Rare Disease climbed 15%, all at CER.

Shares in AstraZeneca eased 1.0% to 13,756.00 pence each in London on Wednesday morning.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 13,620.00 GBX -2.01

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures